View Author
patient vaccination study group response vaccine fluenza therapy control virus atazanavir viremia treatment haart hiv-infected intradermal count hiv-infected patients disease antibody anti-tnf antiretroviral fluenza vaccination netherland concentration episode plasma antiretroviral therapy t-cell influenza effect infection level department titer center intradermal vaccination subject fluenza virus vaccine ifn -␥ production university signi atovaquone william lippincott wilkin number measurement pneumococcal article interruption cancer influenza vaccination appendiciti hospital antigen /ritonavir result ficiency hiv infection mutation immunocompromized patients lopinavir /ritonavir intramuscular production sample change treatment interruption factor month pi mutations intramuscular vaccination women anti-tnf group protection rates mthpc guideline serotype protection study groups
9 Most Recent Publications
|
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
(Article)
Luin, M. van Ende, M.E. van der Kuks, P.F. Burger, D.M. Richter, C. Visser, M. Faraj, D. Ven, A. van der Gelinck, L.B.S. Kroon, F.P. Wit, F.W. Schaik, R.H.N. van |
2010-05-01
|
|
Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III
(Article)
Snoek, E.M. van der Amelink, A. Ende, M.E. van der Hollander, J.C. den Kroon, F.P. Vriesendorp, R. Neumann, H.A.M. Robinson, D.J. |
2009-09-01
|
|
Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible
(Article)
Gelinck, L.B.S. Bemt, B.J.F. van den Marijt, W.A.F. Bijl, A.E. van der Visser, L.G. Cats, H.A. Rimmelzwaan, G.F. Kroon, F.P. |
2009-04-21
|
|
Influenza virus vaccination induces interleukin-12/23 receptor β1 (IL-12/23Rβ1)-independent production of gamma interferon (IFN-γ) and humoral immunity in patients with genetic deficiencies in IL-12/23Rβ1 or IFN-γ receptor I
(Article)
Boer, T. de Dissel, J.T. van Kuijpers, T.W. Rimmelzwaan, G.F. Kroon, F.P. Ottenhoff, T.H.M. |
2008-08-01
|
|
The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination
(Article)
Gelinck, L.B.S. Bijl, A.E. van der Beyer, W.E.Ph. Visser, L.G. Huizinga, T.W.J. Hogezand, R.A. van Rimmelzwaan, G.F. Kroon, F.P. |
2008-05-01
|
|
Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy
(Article)
Sighem, A. van Zhang, S. Reiss, P. Gras, L. Ende, M.E. van der Kroon, F.P. Prins, J.M. Wolf, F. de |
2008-05-01
|
|
Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab [4]
(Article)
Gelinck, L.B.S. Teng, Y.K.O. Rimmelzwaan, G.F. Bemt, B.J.F. van den Kroon, F.P. Laar, J.M. van |
2007-10-01
|
|
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
(Article)
Cleijsen, R.M.M. Ende, M.E. van der Kroon, F.P. Lunel, verduyn F. Koopmans, P.P. Gras, L. Wolf, F. de Burger, D.M. |
2007-10-01
|
|
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands study (TRIESTAN)
(Article)
Pogány, K. Vanvalkengoed, I.G. Brinkman, K. Prins, J.M. Nieuwkerk, P.T. Ende, I.D. Kauffmann, R.H. Kroon, F.P. Verbon, A. Nievaard, M.F. Lange, J.M.A. |
2007-04-01
|
